What makes anti-angiogenesis drugs a promising strategy in cancer therapies?
Many experiments showed that tumor growth and metastasis are angiogenesis-dependent. Tumors cannot grow unless they recruit their own private blood supply. That is why microvascular endothelial cells [the cells lining capillaries], which are essential for new blood vessel growth, have become an important target in cancer therapy. Antiangiogenic compounds do not attack the tumor cells directly, as chemotherapies do. Instead they turn endothelial cells off, so they wont make new blood vessels, and the tumor will eventually stop growing. The effect of angiostatin and endostatin is tumor-specific. So you have very few, if any, adverse effects on the organism. Targeting endothelial cells has some advantages: these cells are genetically stable, meaning that they do not mutate. In contrast, tumor cells tend to mutate and in this way they often become drug-resistant. Therefore, development of acquired drug resistance, which is common with chemotherapy, is less likely with angiogenesis inhibito
Related Questions
- Can conventional cancer therapies, including chemotherapy and radiation, work with natural medicine?
- Can conventional cancer therapies, including chemotherapy and radiation, work with natural medicine?
- Is Oncology Esthetics safe for people undergoing cancer therapies and during recovery?
- Is Oncology Esthetics safe for people undergoing cancer therapies and during recovery?
- Where can I find more information on alternative and complementary cancer therapies?
- What makes anti-angiogenesis drugs a promising strategy in cancer therapies?
